Sigma Investment Counselors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.86M Sell
31,238
-2,491
-7% -$536K 0.38% 47
2026
Q1
$7.34M Sell
33,729
-2,113
-6% -$469K 0.39% 47
2025
Q4
$8.19M Sell
35,842
-1,509
-4% -$344K 0.42% 48
2025
Q3
$8.65M Sell
37,351
-250
-0.7% -$50.9K 0.45% 45
2025
Q2
$6.98M Buy
37,601
+1,072
+3% +$199K 0.38% 48
2025
Q1
$7.65M Sell
36,529
-2,463
-6% -$479K 0.47% 43
2024
Q4
$6.93M Sell
38,992
-347
-0.9% -$63.8K 0.41% 50
2024
Q3
$7.77M Sell
39,339
-278
-0.7% -$51.9K 0.46% 49
2024
Q2
$6.8M Buy
39,617
+478
+1% +$79.2K 0.43% 50
2024
Q1
$7.13M Sell
39,139
-1,130
-3% -$195K 0.46% 48
2023
Q4
$6.24M Sell
40,269
-3,936
-9% -$574K 0.44% 48
2023
Q3
$6.59M Sell
44,205
-603
-1% -$88.5K 0.5% 45
2023
Q2
$6.04M Buy
44,808
+982
+2% +$144K 0.44% 47
2023
Q1
$6.98M Buy
43,826
+484
+1% +$74K 0.54% 38
2022
Q4
$7M Sell
43,342
-586
-1% -$89.9K 0.58% 36
2022
Q3
$5.9M Sell
43,928
-534
-1% -$76.6K 0.5% 39
2022
Q2
$6.81M Buy
44,462
+22
+0% +$3.36K 0.55% 38
2022
Q1
$7.2M Sell
44,440
-756
-2% -$110K 0.52% 38
2021
Q4
$6.12M Sell
45,196
-65
-0.1% -$7.68K 0.43% 43
2021
Q3
$4.88M Buy
45,261
+1,348
+3% +$154K 0.36% 51
2021
Q2
$4.95M Sell
43,913
-1
-0% -$113 0.37% 49
2021
Q1
$4.75M Sell
43,914
-197
-0.4% -$21.1K 0.39% 46
2020
Q4
$4.73M Buy
44,111
+21,139
+92% +$2.03M 0.41% 47
2020
Q3
$2.01M Sell
22,972
-22,538
-50% -$2.12M 0.39% 49
2020
Q2
$4.47M Buy
45,510
+4,050
+10% +$357K 0.47% 44
2020
Q1
$3.16M Buy
41,460
+268
+0.7% +$22.8K 0.4% 48
2019
Q4
$3.65M Buy
41,192
+81
+0.2% +$6.72K 0.38% 50
2019
Q3
$3.11M Sell
41,111
-2,485
-6% -$170K 0.35% 50
2019
Q2
$3.17M Buy
43,596
+678
+2% +$53.3K 0.37% 49
2019
Q1
$3.46M Sell
42,918
-567
-1% -$46.4K 0.42% 47
2018
Q4
$4.01M Sell
43,485
-508
-1% -$44.7K 0.56% 37
2018
Q3
$4.16M Sell
43,993
-146
-0.3% -$13.8K 0.52% 30
2018
Q2
$4.09M Buy
44,139
+48
+0.1% +$4.69K 0.54% 27
2018
Q1
$4.17M Sell
44,091
-539
-1% -$59.2K 0.57% 28
2017
Q4
$4.32M Sell
44,630
-1,070
-2% -$101K 0.59% 30
2017
Q3
$4.06M Sell
45,700
-1,109
-2% -$84.4K 0.58% 30
2017
Q2
$3.39M Sell
46,809
-590
-1% -$39.7K 0.52% 32
2017
Q1
$3.09M Sell
47,399
-3,371
-7% -$212K 0.49% 41
2016
Q4
$3.18M Sell
50,770
-1,021
-2% -$62.3K 0.51% 37
2016
Q3
$3.27M Buy
51,791
+111
+0.2% +$7.19K 0.54% 36
2016
Q2
$3.2M Buy
51,680
+35
+0.1% +$2.13K 0.55% 38
2016
Q1
$2.95M Buy
51,645
+581
+1% +$32.4K 0.52% 41
2015
Q4
$3.02M Buy
51,064
+1,467
+3% +$84.5K 0.56% 40
2015
Q3
$2.7M Buy
49,597
+531
+1% +$34.6K 0.52% 39
2015
Q2
$3.3M Sell
49,066
-902
-2% -$58.9K 0.61% 35
2015
Q1
$2.92M Sell
49,968
-2,027
-4% -$122K 0.55% 44
2014
Q4
$3.4M Buy
51,995
+1
+0% +$63 0.64% 40
2014
Q3
$3M Sell
51,994
-169
-0.3% -$9.38K 0.58% 43
2014
Q2
$2.94M Sell
52,163
-1,240
-2% -$65.1K 0.57% 45
2014
Q1
$2.75M Buy
53,403
+74
+0.1% +$3.74K 0.55% 46
2013
Q4
$2.82M Buy
53,329
+15,721
+42% +$773K 0.61% 48
2013
Q3
$1.68M Sell
37,608
-70
-0.2% -$3.1K 0.39% 62
2013
Q2
$1.56M Buy
+37,678
New +$1.65M 0.41% 65

Other funds holding ABBV

Sigma Investment Counselors's ABBV Position: Q2 2026 in Review

Sigma Investment Counselors reduced its AbbVie (ABBV) stake by 7.4% in Q2 2026, selling an estimated $536K and leaving 31,238 shares worth $7.86M. The position accounts for 0.38% of the portfolio, ranked #47.

Sigma Investment Counselors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.65M in Q3 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sigma Investment Counselors held 31,238 shares of AbbVie worth $7.86M as of Q2 2026.
  • Sigma Investment Counselors sold 2,491 AbbVie shares in Q2 2026, an estimated $536K.
  • AbbVie made up 0.38% of Sigma Investment Counselors's portfolio in Q2 2026, its #47 holding.
  • Sigma Investment Counselors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Sigma Investment Counselors's AbbVie position peaked at $8.65M in Q3 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sigma Investment Counselors's 13F filing for Q2 2026, filed 28 Jul 2026.